
**FRANCE DIABETES CARE DEVICES MARKET**

According to Intelli, the France diabetes care devices market was valued at USD 1,285.7 million in 2024 and is projected to reach USD 2111.74 million by 2032, growing at a CAGR of 7.3% from 2024 to 2032.

A close-up of hands holding a tablet and a pen

Description automatically generated

The diabetes care devices market in France is growing steadily due to the increasing prevalence of diabetes, the rise in obesity rates, and technological advancements in blood glucose monitoring and insulin delivery systems. The adoption of continuous glucose monitoring systems (CGMs), smart insulin pens, and integrated digital health platforms has facilitated better diabetes management among patients. Additionally, supportive healthcare infrastructure and favorable reimbursement policies are aiding the market’s expansion. Innovations from key players and collaborations between tech companies and healthcare providers are accelerating growth opportunities in the French market.

**France Diabetes Care Devices Market Definition**

Diabetes care devices refer to medical instruments used to manage and monitor blood glucose levels in individuals with diabetes. These devices include self-monitoring blood glucose (SMBG) systems, continuous glucose monitors (CGMs), insulin delivery systems like pumps, pens, and syringes. They are designed to help patients maintain optimal glucose levels and reduce the risk of diabetes-related complications. These devices are used in both clinical and homecare settings and are increasingly being integrated with mobile applications and cloud-based platforms to support real-time monitoring and telehealth consultations. Technological evolution, such as app-connected CGMs and smart insulin delivery systems, is shaping the future of diabetes care and improving adherence and patient outcomes.

**France Diabetes Care Devices Market Overview**

The diabetes care devices market in France is advancing steadily. Factors such as a growing diabetic population, aging demographics, and government efforts toward early diagnosis and diabetes management are positively impacting the market. A growing demand for remote patient monitoring and the rising integration of AI in healthcare are pushing the boundaries of innovation. France has also been proactive in adopting digital health solutions, especially CGM A close-up of hands holding a tablet and a pen

Description automatically generatedand insulin patch pumps.

Despite the progress, challenges such as device affordability, data security concerns, and limited awareness about advanced systems in rural regions remain. Nonetheless, emerging technologies and public-private partnerships offer significant future opportunities.

**France Diabetes Care Devices Market Segmentation Analysis**

Market Segmentation by Product Type:

• Self-Monitoring Devices

• Continuous Glucose Monitoring (CGM) Devices

• Insulin Pumps • Insulin Pens

• Insulin Syringes • Others

Self-monitoring devices hold a substantial share due to their ease of use and affordability. However, the CGM segment is growing rapidly owing to better glucose trend visibility and digital integration.

**Market Segmentation by End-User:**

• Hospitals

• Homecare Settings

• Clinics and Diagnostic Centers

• Others

Hospitals remain a dominant segment due to large-scale procurement and infrastructure support. Homecare is rapidly growing as patients seek convenience and real-time control over their glucose levels.

**Market Segmentation by Geography: A close-up of hands holding a tablet and a pen

Description automatically generated**

• Northern France

• Central France

• Southern France

Urbanized regions in Northern and Central France lead due to better healthcare access and awareness. Growth potential exists in Southern France with rising investments in healthcare outreach.

**Key Players**

The "France Diabetes Care Devices Market" study report includes major players such as Medtronic PLC, Abbott Laboratories, Dexcom Inc., Roche, Becton Dickinson (BD), Novo Nordisk, Eli Lilly, Ypsomed AG, and Tandem Diabetes Care. Our analysis includes financials, product benchmarking, and SWOT analysis for each.

**Key Developments**

* **June 2024**: Dexcom secured reimbursement access for its Dexcom ONE CGM sensor for approximately 100,000 individuals in France with type 2 diabetes on basal insulin therapy (less than three injections per day) and with HbA1c levels ≥8%.
* **September 2023**: Dexcom announced the reimbursement availability of its Dexcom ONE real-time continuous glucose monitoring (CGM) sensor in France. This expansion provides access to over 500,000 individuals with type 1 and type 2 diabetes, aged two years and older, who are undergoing intensive insulin therapy (via external pump or more than three injections per day). ​

**Market Attractiveness**

The French diabetes care devices market is attractive due to favorable policies, increasing disease prevalence, and patient demand for smarter, connected solutions. It presents strong growth prospects in urban and semi-urban areas.

**Porter’s Five Forces**

The competitive environment is intense, with high industry rivalry. Buyer power is strong due to product choices and pricing sensitivity. Regulatory barriers for new entrants are high, while A close-up of hands holding a tablet and a pen

Description automatically generatedsupplier power remains moderate.

**TABLE OF CONTENTS**

1. **INTRODUCTION OF FRANCE DIABETES CARE DEVICES MARKET**1.1 Overview of the Market   
   1.2 Scope of Report   
   1.3 Assumptions
2. **EXECUTIVE SUMMARY**
3. **RESEARCH METHODOLOGY**3.1 Data Mining   
   3.2 Validation   
   3.3 Primary Interviews   
   3.4 List of Data Sources
4. **FRANCE DIABETES CARE DEVICES MARKET OUTLOOK**4.1 Overview   
   4.2 Market Dynamics A close-up of hands holding a tablet and a pen

   Description automatically generated  
   4.2.1 Drivers    
   4.2.2 Restraints    
   4.2.3 Opportunities    
   4.2.4 Trends    
   4.3 Porters Five Force Model   
   4.4 Value Chain Analysis
5. **FRANCE DIABETES CARE DEVICES MARKET, BY PRODUCT TYPE**5.1 Self-Monitoring Devices   
   5.2 Continuous Glucose Monitoring (CGM) Devices   
   5.3 Insulin Pumps   
   5.4 Insulin Pens   
   5.5 Insulin Syringes   
   5.6 Others
6. **FRANCE DIABETES CARE DEVICES MARKET, BY END USER**6.1 Hospitals   
   6.2 Homecare Settings   
   6.3 Clinics and Diagnostic Centers   
   6.4 Others
7. **A close-up of hands holding a tablet and a pen

   Description automatically generatedFRANCE DIABETES CARE DEVICES MARKET, BY GEOGRAPHY**7.1 Northern France   
   7.2 Central France   
   7.3 Southern France
8. **FRANCE DIABETES CARE DEVICES MARKET COMPETITIVE LANDSCAPE**8.1 Overview   
   8.2 Company Market Ranking   
   8.3 Key Development Strategies
9. **COMPANY PROFILES  
   9.1 Medtronic PLC**9.1.1 Overview    
   9.1.2 Financial Performance    
   9.1.3 Product Outlook    
   9.1.4 Key Developments    
   **9.2 Abbott Laboratories**9.2.1 Overview    
   9.2.2 Financial Performance    
   9.2.3 Product Outlook    
   9.2.4 Key Developments    
   **9.3 Dexcom Inc.**9.3.1 Overview    
   9.3.2 Financial Performance    
   9.3.3 Product Outlook    
   9.3.4 Key Developments    
   **9.4 Roche**9.4.1 Overview    
   9.4.2 Financial Performance    
   9.4.3 Product Outlook    
   9.4.4 Key Developments    
   **9.5 Becton Dickinson (BD)**9.5.1 Overview    
   9.5.2 Financial Performance    
   9.5.3 Product Outlook    
   9.5.4 Key Developments    
   **9.6 Novo Nordisk**9.6.1 Overview    
   9.6.2 Financial Performance    
   9.6.3 Product Outlook    
   9.6.4 Key Developments    
   **9.7 Eli Lilly**9.7.1 Overview    
   9.7.2 Financial Performance    
   9.7.3 Product Outlook    
   9.7.4 Key Developments    
   **9.8 Ypsomed AG**9.8.1 Overview    
   9.8.2 Financial Performance    
   9.8.3 Product Outlook    
   9.8.4 Key Developments    
   **9.9 Tandem Diabetes Care**9.9.1 Overview    
   9.9.2 Financial Performance    
   9.9.3 Product Outlook    
   9.9.4 Key Developments
10. **A close-up of hands holding a tablet and a pen

    Description automatically generatedKEY DEVELOPMENTS**10.1 Product Launches/Developments   
    10.2 Mergers and Acquisitions   
    10.3 Business Expansions   
    10.4 Partnerships and Collaborations
11. **A close-up of hands holding a tablet and a pen

    Description automatically generatedAPPENDIX**11.1 Related Research